October 23, 2024- BD announced a strategic collaboration with Ypsomed, a leading developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs. The BD Neopak™ XtraFlow™ Glass Prefillable Syringe is BD’s latest portfolio addition, featuring a shorter, 8-millimeter needle length, and thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles.
To support this innovation, Ypsomed is expanding its YpsoMate® 2.25 two-step autoinjector platform to accommodate the new syringe format. This includes adapting parts of the autoinjector for the shorter needle, qualifying tooling and assembly, and performing extensive technical testing to ensure reliability. The YpsoMate autoinjector device is handled in two steps: simply remove the cap and push on skin, designed so that people with impaired grip or vision can administer their medication easily and safely.
In a joint project, Ypsomed and BD have pre-assessed and streamlined integration of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe with Ypsomed’s YpsoMate® 2.25 autoinjector platform, addressing current limitations by enabling the delivery of higher viscosity (>15cP) biologic drugs in an autoinjector format.